Page 64 - EASL POSTGRADUATE COURSE
P. 64
References
[1] Francque S. The role of non-alcoholic fatty liver disease in cardiovascular disease. European
Cardiology Review 2014;9:10-15.
[2] Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic
complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol
2014;20:1724-1745.
[3] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular
disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344.
[4] Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic
syndrome. Lancet Diabetes Endocrinol 2014;2:901-910.
[5] Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of
clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
[6] Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of
chronic liver disease and death. Gut 2004;53:750-755.
[7] Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a
population-based cohort study. Gastroenterology 2005;129:113-121.
[8] Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and
elevated liver enzymes. Hepatology 2006;44:865-873.
[9] Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin
Gastroenterol Hepatol 2009;7:234-238.
[10] Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function
tests during a 28-year follow-up. Hepatology 2010;51:595-602.
[11] Athyros VG,Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for
cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek
Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Lancet 2010;376:1916-1922.
[12] Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin
on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline
elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-3852.
64 Postgraduate Course Syllabus • Metabolic Liver Disease
[1] Francque S. The role of non-alcoholic fatty liver disease in cardiovascular disease. European
Cardiology Review 2014;9:10-15.
[2] Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic
complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol
2014;20:1724-1745.
[3] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular
disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344.
[4] Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic
syndrome. Lancet Diabetes Endocrinol 2014;2:901-910.
[5] Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of
clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
[6] Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of
chronic liver disease and death. Gut 2004;53:750-755.
[7] Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a
population-based cohort study. Gastroenterology 2005;129:113-121.
[8] Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and
elevated liver enzymes. Hepatology 2006;44:865-873.
[9] Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin
Gastroenterol Hepatol 2009;7:234-238.
[10] Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function
tests during a 28-year follow-up. Hepatology 2010;51:595-602.
[11] Athyros VG,Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for
cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek
Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Lancet 2010;376:1916-1922.
[12] Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin
on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline
elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-3852.
64 Postgraduate Course Syllabus • Metabolic Liver Disease
